title: Promoter hypermethylation profiling of distant breast cancer metastases.
abstract: Promoter hypermethylation of tumor suppressor genes seems to be an early event in breast carcinogenesis and is potentially reversible. This makes methylation a possible therapeutic target, a marker for treatment response and/or a prognostic factor. Methylation status of 40 tumor suppressor genes was compared between 53 primary breast tumors and their corresponding metastases to brain, lung, liver, or skin. In paired analyses, a significant decrease in methylation values was seen in distant metastases compared to their primaries in 21/40 individual tumor suppressor genes. Furthermore, primary tumors that metastasized to the liver clustered together, in line with the finding that primary breast carcinomas that metastasized to the brain, skin, or lung, showed higher methylation values in up to 27.5 % of tumor suppressor genes than primary carcinomas that metastasized to the liver. Conversion in methylation status of several genes from the primary tumor to the metastasis had prognostic value, and methylation status of some genes in the metastases predicted survival after onset of metastases. Methylation levels for most of the analyzed tumor suppressor genes were lower in distant metastases compared to their primaries, pointing to the dynamic aspect of methylation of these tumor suppressor genes during cancer progression. Also, specific distant metastatic sites seem to show differences in methylation patterns, implying that hypermethylation profiles of the primaries may steer site-specific metastatic spread. Lastly, methylation status of the metastases seems to have prognostic value. These promising findings warrant further validation in larger patient cohorts and more tumor suppressor genes.
authors.affiliation: Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584, Utrecht, CX, The Netherlands, w.a.m.schrijver@umcutrecht.nl.
authors.forename: Willemijne A M E
authors.initials: WA
authors.lastname: Schrijver
authors.forename: Laura S
authors.initials: LS
authors.lastname: Jiwa
authors.forename: Paul J
authors.initials: PJ
authors.lastname: van Diest
authors.forename: Cathy B
authors.initials: CB
authors.lastname: Moelans
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology / Q000556:secondary; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D019175:DNA Methylation / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics / Q000473:pathology / Q000556:secondary; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011379:Prognosis; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000096:biosynthesis; D012878:Skin Neoplasms / Q000235:genetics / Q000473:pathology / Q000556:secondary; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D012333:RNA, Messenger; D025521:Tumor Suppressor Proteins
references.citation: Virchows Arch. 2013 Jan;462(1):47-56
references.pmid: 23224118
references.citation: Oncogene. 2010 Aug 26;29(34):4814-25
references.pmid: 20543860
references.citation: BMC Cancer. 2014;14:245
references.pmid: 24708595
references.citation: Breast Cancer Res Treat. 2011 Aug;128(3):795-805
references.pmid: 21311969
references.citation: Breast Cancer Res. 2010;12(5):R75
references.pmid: 20863372
references.citation: Mamm Genome. 2011 Apr;22(3-4):249-59
references.pmid: 21373886
references.citation: J Transl Med. 2010;8:86
references.pmid: 20849603
references.citation: Cancer Res. 2005 Aug 15;65(16):7081-5
references.pmid: 16103055
references.citation: Breast Cancer Res Treat. 2012 Dec;136(3):705-15
references.pmid: 23104224
references.citation: Genet Mol Biol. 2012 Dec;35(4):714-24
references.pmid: 23271929
references.citation: Mod Pathol. 2014 Jun;27(6):869-74
references.pmid: 24287456
references.citation: Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42
references.pmid: 12808139
references.citation: Ann Oncol. 2013 Dec;24(12):3017-23
references.pmid: 24114857
references.citation: Ann Oncol. 2008 Nov;19(11):1870-4
references.pmid: 18647968
references.citation: Clin Cancer Res. 2008 Apr 1;14(7):1938-46
references.pmid: 18381931
references.citation: Sci Signal. 2013 Apr 2;6(269):pl1
references.pmid: 23550210
references.citation: Cancer Biol Ther. 2011 May 15;11(10):853-65
references.pmid: 21383541
references.citation: Virchows Arch. 2011 Jan;458(1):73-84
references.pmid: 21120523
references.citation: Breast Cancer Res Treat. 2009 Mar;114(2):315-25
references.pmid: 18404369
references.citation: J Med Genet. 2003 Jan;40(1):25-33
references.pmid: 12525538
references.citation: Neoplasma. 2013;60(3):290-4
references.pmid: 23373998
references.citation: Anal Cell Pathol (Amst). 2010;33(3):133-41
references.pmid: 20978321
references.citation: Breast Cancer Res Treat. 2009 Aug;116(3):471-8
references.pmid: 18686028
references.citation: Cancer Cell. 2005 Sep;8(3):227-39
references.pmid: 16169467
references.citation: Oral Oncol. 2014 Apr;50(4):291-7
references.pmid: 24444674
references.citation: Eur J Hum Genet. 2012 Dec;20(12):1256-64
references.pmid: 22763379
references.citation: Sci Transl Med. 2013 Jan 23;5(169):169ra10
references.pmid: 23345608
references.citation: Cancer Metastasis Rev. 1989 Aug;8(2):98-101
references.pmid: 2673568
references.citation: Breast Cancer Res Treat. 2013 Nov;142(2):365-80
references.pmid: 24212716
references.citation: Cancer. 2012 Oct 15;118(20):4929-35
references.pmid: 22415862
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3271-7
references.pmid: 20498394
references.citation: BMJ. 2002 Sep 21;325(7365):648-51
references.pmid: 12242180
references.citation: Eur J Cancer. 2004 Feb;40(3):336-41
references.pmid: 14746850
references.citation: PLoS One. 2014;9(1):e85448
references.pmid: 24489661
references.citation: J Clin Oncol. 2009 Apr 1;27(10):1549-56
references.pmid: 19237635
references.citation: Semin Cancer Biol. 2012 Jun;22(3):226-33
references.pmid: 22504658
references.citation: J Pathol. 2011 Oct;225(2):222-31
references.pmid: 21710692
references.citation: Breast Cancer Res Treat. 2006 Nov;100(2):229-35
references.pmid: 16932852
references.citation: Breast Cancer Res Treat. 2013 Jan;137(2):383-96
references.pmid: 23239149
references.citation: J Mammary Gland Biol Neoplasia. 2012 Dec;17(3-4):191-204
references.pmid: 22836913
references.citation: Cancer Discov. 2012 May;2(5):401-4
references.pmid: 22588877
references.citation: Ann Hematol. 2013 Jan;92(2):199-209
references.pmid: 23093371
references.citation: Cancer Cell. 2008 May;13(5):441-53
references.pmid: 18455127
references.citation: Nat Rev Cancer. 2009 Apr;9(4):302-12
references.pmid: 19308069
references.citation: Clin Cancer Res. 2004 May 1;10(9):3104-9
references.pmid: 15131050
references.citation: Int J Cancer. 2012 Nov 15;131(10):2308-19
references.pmid: 22362391
references.citation: Br J Surg. 2011 May;98(5):724-34
references.pmid: 21360524
references.citation: Mol Cell Biochem. 2014 Nov;396(1-2):67-77
references.pmid: 25148870
references.citation: J Biol Chem. 2000 Jan 28;275(4):2727-32
references.pmid: 10644736
references.citation: Exp Mol Pathol. 2007 Oct;83(2):188-97
references.pmid: 17540367